RepliCel Life Sciences Inc.
RP
Rang in Aktien
#38675
Headquartered in Vancouver, Canada, RepliCel Life Sciences Inc. is a... Headquartered in Vancouver, Canada, RepliCel Life Sciences Inc. is a regenerative medicine company dedicated to developing innovative autologous cell therapies. These treatments are designed to correct functional cellular deficiencies by harnessing a patient's own cells. The process involves isolating cells from harvested tissues, significantly expanding them in a controlled laboratory environment, and subsequently applying them therapeutically. The company's developmental portfolio includes several key product candidates: RCT-01 targets chronic tendinosis, RCS-01 addresses aging and sun-damaged skin, and RCH-01 is aimed at treating hair loss. Additionally, RepliCel is advancing RCI-02, a specialized dermal injection device. RepliCel has established significant strategic alliances. It holds a collaboration and technology transfer agreement with YOFOTO (China) Health Industry Co. Ltd. to establish a clinical research program and facilitate the commercialization of RCS-01 and RCT-01. A similar collaboration exists with Shiseido Company, Limited, focusing on the clinical research program for RCH-01. Furthermore, the company is engaged in a research project agreement with the University of British Columbia, contributing to the creation of a comprehensive hair follicle cell data map.
Aktienkurs
$0.01100905
Zuletzt synchronisiert: 2025-02-28
Marktkapitalisierung
$810.02K
Veränderung (1 Tag)
58.98%
Veränderung (1 Jahr)
10,909.05%
Land
CA
Handel RepliCel Life Sciences Inc. (RP)
Kategorie
Healthcare
Kursverlauf für RepliCel Life Sciences Inc. (RP)
Höchster Schlusskurs: $0.00 am 2026-10-01
Niedrigster Schlusskurs: $0.16 am 2010-05-01
Niedrigster Schlusskurs: $0.16 am 2010-05-01
Kursverlauf der Aktie von RepliCel Life Sciences Inc. von 2010 bis 2026
Jährliche Kursentwicklung
| Jahr | Leistung |
|---|---|
| 2026 (TTM) | 0.00% |
| 2025 | -95.09% |
| 2024 | -63.87% |
| 2023 | -25.97% |
| 2022 | -62.91% |
| 2021 | 19.36% |
| 2020 | -9.55% |
| 2019 | -29.32% |
| 2018 | -23.47% |
| 2017 | -44.02% |
| 2016 | -66.76% |
| 2015 | -35.40% |
| 2014 | -42.41% |
| 2013 | -10.99% |
| 2012 | -75.85% |
| 2011 | 47.04% |
| 2010 | 0.00% |
Aktienkurs vergleichbarer Unternehmen oder Wettbewerber
| Unternehmen | Aktienkurs | Veränderung 1J% | Land |
|---|---|---|---|
| $514.04 | 20.59% |
US
|
|
| $241.53 | 778.61% |
US
|
|
| $138.33 | -3.31% |
AU
|
|
| $812.85 | 15.96% |
CH
|
|
| $875.26 | 4.85% |
NL
|
